

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Laboratorios Pfizer Ltda.	Grant / Contract	Self

Recipient Name: Yaniv Lustig
Grant / Contract Description: The prevalence of Tick Borne Encephalitis (TBE) infection in neurologic patients in Israel
Recipient Type: Individual
Grant / Contract Purpose: Research
Additional Information: I received a grant from Pfizer on a non related topic (TBE infections in Israel)

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 22-02542

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Gili Regev-Yochay

Disclosure Purpose: 22-02542

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Meeting on Vaccine AE
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Lecture on Merck Asia-Pacific Webinar
Moderna	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Advisory board
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Gili Regev-Yochay <i>Grant / Contract Description:</i> Pneumococcal Disease / COVID vaccine <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Teva Pharmaceutical Industries	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Lectures on fluids and infection control

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Fourth Dose COVID mRNA Vaccine Efficacy Against Omicron
- Are you the corresponding author?**
Yes.
 - Please list the other authors' names here.**
Tal Gonen, Mayan Gilboa, Michal Mandelboim, Victoria Indenbaum, Sharon Amit, Lilac Meltzer, Keren Asraf, Carmit Cohen, Ronen Fluss, Asaf Biber, Itai Nemet, Limor Kliker, Gili Joseph, Ram Doolman, Ella Mendelson, Laurence S. Freedman, Dror Harats, Yitshak Kreiss and Yaniv Lustig

Certification

I certify that the information provided in this disclosure is complete and accurate.